An observational study in Acute Respiratory Distress Syndrome, COVID-19 Pneumonia and Recruitment, sponsored by Ramos Mejía Hospital. Recruiting at 1 site in Argentina. Open to participants aged 15 Years and older. Per ClinicalTrials.gov, last updated 2023-11-13.
Sponsored by Ramos Mejía Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Respiratory Distress Syndrome with a site in Argentina — 6 open to participants now, 7 under way, 1 of them phase 3. Respiratory Distress Syndrome · Argentina.
Among the 21 studies in Respiratory Distress Syndrome with a site in Argentina, this one is the 6th largest by planned enrollment of the 12 observational ones that give a count, is one of 4 that started in 2022, is one of 12 observational ones, and was the 13th registered.
1,389 studies on the registry are indexed under Respiratory Distress Syndrome; 281 are open to participants now.
Browse Respiratory Distress Syndrome studies →6 of the 21 studies in Respiratory Distress Syndrome with a site in Argentina are open now. Recruiting first, the newest first:
Hospital de Alta Complejidad en Red · Sites in Argentina
Ages 1 mo–14 yrs
Pontificia Universidad Catolica de Chile · Sites in Argentina, Chile, Colombia and 3 more countries
Ages 18+
Hospital El Cruce · Sites in Argentina
Ages 18–75
AstraZeneca · Sites in Argentina, United States, Australia and 36 more countries
Ages 18+
Sanatorio Anchorena San Martin · Sites in Argentina
Ages 18+
A study can be open while its sites in Argentina have not opened yet or have stopped. Only those recruiting at a site in Argentina →
Of the 196 Respiratory Distress Syndrome studies recruiting now, 116 (59%) set no upper age limit and 50 (26%) stop at 75 or younger; 52 take children under 18; 9 take healthy volunteers.
This study: 15 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 4 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 41 is below the median of 100 across 476 observational studies indexed under Respiratory Distress Syndrome.
Median enrollment 107 across the 9 interventional studies, 40 across the 12 observational. Of the 11 that completed or were terminated, 1 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 21 have an industry lead sponsor. The 10 most frequent:
Ramos Mejía Hospital is the lead sponsor of 4 studies on the registry; 3 are open to participants now.
Ramos Mejía Hospital has 3 studies filed under Respiratory Distress Syndrome — fewer than ten, so there is no comparison to draw.
2 of the studies in Respiratory Distress Syndrome with a site in Argentina that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT06854627Pontificia Universidad Catolica de ChileEffect of Continuous Prolonged Prone Position Versus Intermittent Daily Prone Position in ARDS | 2027-10 |
Add all 2 to your calendar (.ics) → With an account.
Among the 21 studies in Respiratory Distress Syndrome with a site in Argentina, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Respiratory failure associated with Covid-19 can be expressed as acute respiratory distress syndrome (ARDS), which is an acute inflammatory lung injury,which generally requires the use of invasive mechanical ventilation (MV). There are inconclusive results regarding the potential lung recruitment in ARDS.
At the lung level, the relationship between lung volume and pressure can be graphed through a pressure/volume (P/V) curve. In this curve, hysteresis (H) can be evaluated, which is the amount of energy generated during inspiration that is not recovered during expiration. H is related to recruitment, assuming that the greater H the greater the alveolar recruitment. For this reason, the objective of this study is the measurement of H as a way to assess the lung recruitment capacity, in patients with ARDS and in patients with Covid-19 who develop ARDS (ARDS- Covid)
During the first 7 days of the patient on mechanical ventilation (MV), measurements will be taken. For this, the patient will be in the supine position (DS) or the prone position (DP). The patient will be on a dose of analgesics, under sedation and muscle relaxation and will not present any respiratory stimulus.
Data from MV will also be recorded (prior to recruitment assessment): tidal volume (TV) in milliliters (ml), respiratory rate (RR) in a minute, fraction of inspired oxygen (FiO2), positive end-expiratory pressure (PEEP), in centimeters of water (cmH2O), plateau pressure (Pplat, measured after an end-inspiratory pause, cmH2O), mean airway pressure (PM, cmH2O), minute volume (calculated as the product of RR and TV) in milliliters per minute, ∆P (calculated as Pplat minus PEEP, cmH2O), static compliance (calculated as TV divided by ∆P, ml/cmH2O). Arterial blood gases will also be considered.
The proposed recruitment assessment will be the measurement of pulmonary hysteresis ratio. For measurements, a ventilator (Neumovent GraphNet Advance-TS, Córdoba Argentina) will be used. Additionally, a dedicated software connected to a computer will be used to perfThe evaluation of pressure in relation to volume will also be carried out, through the pressure/volume curve (PV curve), available in the respirator. A low-flow inflation and deflation PV curve from 0 up to 40 cm H2O and from 40 down to 0 cm H2O will be performed using the automatic tool on the ventilator (P/V tool; Neumovent GraphNet Advance-ts, Córdoba Argentina). The P-V curve can be visualized immediately on the screen of the mechanical ventilator and will be taken as a method to assess lung recruitment through the hysteresis-like behavior of the respiratory system. Inflation and deflation volume data will be corrected for changes in oxygen consumption.
Ratio hysteresis (RH) of the respiratory system will be measured by planimetry using SigmaPlot 12.0 software. There, through a cursor, for the measurement of hysteresis, the place where the volume was greater was drawn and the coincident pressure value was considered. Subsequently the ratio hysteresis will be calculated as the ratio between hysteresis and the product of the pressure span and the maximum volume reached (maximum hysteresis). Also, through the maximum distance between the inspiratory and expiratory limb of the curve weighted by the maximum volume, the normalized maximum distance (Vmax) is calculated. Recruitment potential will considered when there is a HR ≥ 28% and aVmax ≥ 41%.
Data Analysis. Categorical variables will be presented as number and percentage, while continuous variables will be presented as mean and standard deviation or median and interquartile range, as appropriate. The Chi2 test or Fisher's exact test will be used for qualitative variables and the Student test or the Mann-Whitney U test for quantitative variables. To evaluate correlation, the Pearson or Spearman test will be used, according to the distribution of the evaluated variables. A p ≤ 0.05 will be used.
Patients 15 years of age or older who have been receiving MV in the first 7 days and have been defined as ARDS and ARDS-Covid-19 (with a positive polymerase chain reaction in nasopharyngeal swab samples) according to the clinical criteria of the Berlin definition.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Intervention Details: Construction of the P/V curve with subsequent measurement of HR and Vmax.
Potential recruitment of patients with ARDS and ARDS-Covid-19
Recruitment potential will considered when there is a HR ≥ 28% and Vmax ≥ 41%.
Time frame: First 7 days of the patient on mechanical ventilation (MV)
Assess the association between APACHE II (Acute Physiology And Chronic Health Evaluation) score and and potential recruitment
Assess the correlation between APACHE and potential recruitment (HR ≥ 28% and Vmax ≥ 41%). Tidal volume and pressure will be combined to report the Recruitment Index (R/I) in mL/cmH2O. A threshold of 0.5 will be used to define high recruitability (R/I ratio \>= 0.5 ml/cmH2O) and low recruitability (R/I ratio \< 0.5 ml/cmH2O).
Time frame: First 7 days of the patient on mechanical ventilation (MV)
Assess the association between TV and potential recruitment
Assess the correlation between TV and potential recruitment (HR ≥ 28% and Vmax ≥ 41%).
Time frame: First 7 days of the patient on mechanical ventilation (MV)
Assess the association between plateau pressure and potential recruitment
Assess the correlation between plateau pressure and potential recruitment (HR ≥ 28% and Vmax ≥ 41%). * Oxygenation: PaO2/FiO2 (ratio between arterial oxygen pressure and inspired fraction of oxygen). * Static compliance (cmH2O) * Plateau pressure (cmH2O) * ∆P (ml/cmH2O) Tidal volume and pressure will be combined to report the Recruitment Index (R/I) in mL/cmH2O.
Time frame: First 7 days of the patient on mechanical ventilation (MV)
Assess the association between ΔP and potential recruitment
Assess the correlation between ΔP and potential recruitment (HR ≥ 28% and Vmax ≥ 41%).
Time frame: First 7 days of the patient on mechanical ventilation (MV)
Assess the association between static compliance and potential recruitment
Assess the correlation between static compliance and potential recruitment (HR ≥ 28% and Vmax ≥ 41%).
Time frame: First 7 days of the patient on mechanical ventilation (MV)
Assess the association between mechanical power and potential recruitment
Assess the correlation between mechanical power and potential recruitment (HR ≥ 28% and Vmax ≥ 41%).
Time frame: First 7 days of the patient on mechanical ventilation (MV)
Assess the association between PaO2/FiO2 and potential recruitment
Assess the correlation between PaO2/FiO2 and potential recruitment (HR ≥ 28% and Vmax ≥ 41%).
Time frame: First 7 days of the patient on mechanical ventilation (MV)
Assess the association between PaCO2 and potential recruitment
Assess the correlation between PaCO2 and potential recruitment (HR ≥ 28% and Vmax ≥ 41%).
Time frame: First 7 days of the patient on mechanical ventilation (MV)
Assess the association between ventilator free days (in days) and potential recruitment
Assess the correlation between ventilator free days (in days) and potential recruitment (HR ≥ 28% and Vmax ≥ 41%).
Time frame: First 7 days of the patient on mechanical ventilation (MV)
Plan to share: No
Ran from Mar 2022 to primary completion in Mar 2023, 12 months.
Of 228 non-industry observational studies under Respiratory Distress Syndrome, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's 12 months is below that.
Counting every sponsor, half of 234 studies reached it within 24 months; a quarter within 12 and three quarters within 49.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Respiratory Distress Syndrome →